Modernizing Diabetes Diagnostic Methods

• CURECLIP PHARMACEUTICALS LIMITED
• |
• Diabetes
• |
• Diagnostics

Diabetes mellitus is one of the most prevalent and burdensome chronic diseases in the world, with over 537 million adults living with the condition globally. India bears a particularly heavy burden, with more than 77 million diabetics — the second highest number in the world. Accurate, timely, and accessible diagnostics are therefore not just clinically critical, they are a public health necessity.

CURECLIP PHARMACEUTICALS LIMITED's diabetes diagnostics portfolio encompasses the full spectrum of testing solutions required for effective diabetes management. From fasting plasma glucose and oral glucose tolerance tests (OGTT) to glycated hemoglobin (HbA1c) monitoring and comprehensive metabolic panels, our products provide clinicians with a complete and nuanced picture of a patient's metabolic health.

HbA1c testing remains the gold standard for long-term glycemic monitoring. CURECLIP PHARMACEUTICALS LIMITED manufactures high-precision HbA1c analyzers that use the IFCC-aligned ion-exchange HPLC method, providing results in under 5 minutes with a coefficient of variation below 1% — ensuring the reliability that both clinicians and patients depend on.

Continuous glucose monitoring (CGM) technology is transforming diabetes management from episodic to real-time. CGM devices use small electrochemical sensors inserted just beneath the skin to measure interstitial glucose levels every few minutes, generating alerts for dangerous highs and lows. For patients with Type 1 diabetes and insulin-dependent Type 2 diabetes, CGM has been shown to significantly reduce the incidence of hypoglycemic episodes and improve overall glycemic control.

CURECLIP PHARMACEUTICALS LIMITED is also investing in the next generation of non-invasive glucose monitoring. Using near-infrared spectroscopy and photoplethysmography, we are developing technologies that can estimate blood glucose levels from the skin surface — no needle, no lancet, no blood. While still in the research phase, this technology promises to eliminate one of the most significant barriers to consistent self-monitoring in diabetes care.

"Empowering patients with real-time, accurate glucose data transforms diabetes management from reactive crisis response to proactive, personalized health stewardship." — CURECLIP PHARMACEUTICALS LIMITED Diagnostics Division